Bloom Burton Equities Analysts Raise Earnings Estimates for BioSyent Inc. (CVE:RX)

BioSyent Inc. (CVE:RX) – Equities researchers at Bloom Burton boosted their FY2024 EPS estimates for shares of BioSyent in a report issued on Monday, September 23rd. Bloom Burton analyst D. Martin now expects that the company will earn $0.59 per share for the year, up from their prior estimate of $0.57. The consensus estimate for BioSyent’s current full-year earnings is $0.68 per share. Bloom Burton also issued estimates for BioSyent’s FY2025 earnings at $0.71 EPS and FY2026 earnings at $0.82 EPS.

BioSyent (CVE:RX) last issued its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C$0.13. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. The business had revenue of C$8.95 million for the quarter, compared to analyst estimates of C$8.80 million.

BioSyent Stock Up 0.4 %

CVE:RX opened at C$11.04 on Wednesday. The firm has a market capitalization of C$127.95 million, a P/E ratio of 18.40 and a beta of 0.93. BioSyent has a 1-year low of C$7.75 and a 1-year high of C$11.45. The company’s fifty day moving average price is C$10.42 and its 200-day moving average price is C$9.54. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91.

Insider Transactions at BioSyent

In other news, insider FAX Capital Corp. sold 500,000 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of C$10.05, for a total value of C$5,025,000.00. In other BioSyent news, Director Seyed Ahmad Ashrafi sold 2,320 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of C$10.95, for a total value of C$25,404.00. Also, insider FAX Capital Corp. sold 500,000 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of C$10.05, for a total transaction of C$5,025,000.00. Insiders have sold 502,920 shares of company stock worth $5,057,064 over the last 90 days. 34.21% of the stock is currently owned by company insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.